Medytox(154,100 +6.87%)Announced that Daewoong’s ’21-month import and sale ban’ order for Nabota (export name bulletin), which is a botulinum toxin formulation, will take effect on the 15th (local time).
This is the result of US President Joe Biden’s acceptance of the final decision of the US International Trade Commission (ITC).
As a result, Nabota’s imports into the United States and the sale of Nabota inventory held by Ebolus are banned from the time the order goes into effect.
A Medytox official said, “As the US President accepted the ITC’s final judgment, it was revealed that Daewoong had stolen Medytox strains and manufacturing technology.” He argued that he must also take moral responsibility for making false claims.”
Medytox expects Daewoong and Ebolus to appeal against the ITC ruling and seek ways to prevent the import ban order from taking effect. A company official said, “The claims that Daewoong is expected to raise are already dismissed by the ITC’s Unfair Investigation Bureau, the administrative judge, and the entire ITC committee. I am sure I will refuse.”
“Even if Daewoong appeals to the U.S. Federal Circuit Court of Appeals, it is unlikely that the charges determined guilty will change through extensive evidence. He added that the speed of the prosecution’s investigation will be rapid.”
Reporter Kim Ye-na [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution